RT Journal Article SR Electronic T1 Six of 12 Relapsed or Refractory Indolent Lymphoma Patients Treated 10 Years Ago with 131I-Tositumomab Remain in Complete Remission JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 896 OP 900 DO 10.2967/jnumed.111.087460 VO 52 IS 6 A1 Franz Buchegger A1 Cristian Antonescu A1 Claudine Helg A1 Marek Kosinski A1 John O. Prior A1 Angelika Bischof Delaloye A1 Oliver W. Press A1 Nicolas Ketterer YR 2011 UL http://jnm.snmjournals.org/content/52/6/896.abstract AB The purpose of our study was to update the safety and efficacy results of radioimmunotherapy in relapsed or resistant indolent or transformed non-Hodgkin lymphoma. Methods: More than 9 y ago, we treated 12 indolent and 4 transformed, relapsed or refractory lymphoma patients with a single administration of nonmyeloablative therapy with tositumomab and 131I-tositumomab. The 16 patients had a mean of 3.1 (range, 1–6) previous chemotherapy and antibody treatments. Results: Six of 12 relapsed indolent lymphoma patients remain disease-free a mean of 9.8 y (range, 8.6–10.7 y) after radioimmunotherapy. Three of 4 transformed lymphoma patients progressed after radioimmunotherapy, and 1 patient had a partial response of 10 mo. Conclusion: Optimal patient benefit might be obtained in indolent lymphoma when administering radioimmunotherapy up-front in combination with chemotherapy and rituximab treatment. However, these results show that radioimmunotherapy alone achieved long-lasting remissions in 6 of 12 (50%) indolent lymphoma patients in relapse after 1 or multiple chemotherapies.